What do you do when a “what if” scenario becomes a distinct possibility and has the potential to interrupt your mega-study involving over 10,000 patients in hundreds of sites in various countries around the globe. How do you minimise the risk of treatment interruption, unintentional unblinding and drug wastage if you must switch modes of drug administration mid-study? For one leading pharmaceutical company, the answer was to rely on Almac Clinical Technologies, solutions to provide a contingency plan that could be activated at any moment.